Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279730 | 1.00 | MMP8 (0.51) | MMP8L3MBTL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL135996 | 0.86 | MIF (0.56) | ALDH1A1LMNAPOLBHSD17B10PPARG | |
| SCHEMBL7266856 | 0.86 | ALDH1A1 (0.46) | L3MBTL1SMN1; SMN2ALDH1A1LMNAMIF | |
| SCHEMBL5399978 | 0.86 | MIF (0.56) | ALDH1A1LMNAPOLBHSD17B10PPARG | |
| SCHEMBL820965 | 0.86 | MIF (0.56) | ALDH1A1LMNAPOLBHSD17B10PPARG | |
| SCHEMBL7266845 | 0.86 | ALDH1A1 (0.46) | L3MBTL1SMN1; SMN2ALDH1A1LMNAMIF | |
| SCHEMBL12483826 | 0.82 | ITGA4 (0.48) | POLBMIFMAPT | |
| SCHEMBL10441236 | 0.82 | ITGA4 (0.48) | POLBMIFMAPT | |
| SCHEMBL28122854 | 0.82 | PPARG (0.40) | L3MBTL1PPARGMIFPKM | |
| SCHEMBL21891734 | 0.81 | CHRM1 (0.40) | MMP8PPARGMIFPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838888-B1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9469618-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469618-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160257660-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257660-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9371299-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371299-B2 | Thiadiazolidinediones as GSK-3 inhibitors | ASD THERAPEUTICS PARTNERS, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150038538-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038538-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2015-02-05 | — | — | US | disclosed |
| WO-2013124413-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | NOSCIRA, S.A. (ES) | 2013-08-29 | — | — | WO | disclosed |
| US-6333427-B1 | EXTRACTING OPTICALLY ACTIVE FORM OF N-T-BUTOXYCARBONYLPHENYLALANINE ESTER IN CRUDE PREPARATION INTO ALIPHATIC HYDROCARBON, RECOVERING ESTER PREPARATION HAVING IMPROVED OPTICAL PURITY | MITSUI CHEMICALS, INC. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-1031560-A1 | Process for preparing N-t-butoxycarbonylphenylalanine ester | Mitsui Chemicals, Inc. (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257660-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | MMP8 3158/4885L3MBTL1 4029/4885SMN1; SMN2 2037/4885 |
| US-20150038538-A1 | THIADIAZOLIDINEDIONES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | MMP8 3158/4885L3MBTL1 4029/4885SMN1; SMN2 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.